Over a hundred deaths from variant Creutzfeldt-Jakob disease (vCJD) have now been recorded. The incubation period for vCJD may be up to 40 years and the number of asymptomatic carriers in the population could be as many as 100,000. Confirmed iatrogenic transmission of other human transmissible spongiform encephalopathies raises the possibility of cross-infection from apparently healthy persons who are incubating vCJD. Decontamination techniques routinely used in general dental practice are incapable of inactivating the infective protein responsible for transmitting the disease. So far, no evidence exists to preclude the risk of iatrogenic infection occurring during dental procedures. The author reviews present knowledge of the infective agent, its transmissibility, its origins, current guidelines and the implications for dental practice.
PorterS, ScullyC, RidgwayGL, BellJ.The human transmissible spongiform encephalopathies (TSEs): implications for dental practitioners. Br Dent J2000;188:432–6.
2.
ChenSG, TeplowDB, ParchiP, TellerJK, GambettiP, Autilio-GambettiL.Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem1995;270:19173–80.
3.
PammerJ, CrossHS, FrobertY, TschachlerE, OberhuberG.The pattern of prion-related protein expression in the gastrointestinal tract. Virchows Arch2000;436:466–72.
4.
FerrerI, PuigB, BlancoR, MartiE.Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt-Jakob disease. Neuroscience2000;97:715–26.
5.
FroshA.Prions and the ENT surgeon. J Laryngol Otol1999;113:1064–7.
6.
FraserJR.Infectivity in extraneural tissues following intraocular scrapie infection. J Gen Virol1996;77:2663–8.
7.
BrownP, PreeceM, BrandelJP, SatoT, McShaneL, ZerrI, . Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology2000;55:1075–81.
8.
HillAF, DesbruslaisM, JoinerS, SidleKC, GowlandI, CollingeJ, . The same prion strain causes vCJD and BSE. Nature1997;389:448–50, 526.
9.
PriolaSA.Similar protein signatures for BSE and vCJD. Nat Med1996;2:1303–4.
10.
LorainsJW, HenryC, AgbamuDA, RossiM, BishopM, WillRG, . Variant Creutzfeldt-Jakob disease in an elderly patient. Lancet2001;357:1339–40.
11.
HiltonDA, FathersE, EdwardsP, IronsideJW, ZajicekJ.Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet1998;352:703–4.
12.
FosterPR.Prions and blood products. Ann Med2000;32:501–13.
13.
DyerO.Hospitals to spend 200m pounds to prevent spread of vCJD. BMJ2001;322:68A.
14.
AndrewsNJ, FarringtonCP, CousensSN, SmithPG, WardH, KnightRS, . Incidence of variant Creutzfeldt-Jakob disease in the UK. Lancet2000;356:481–2.
IronsideJW, HiltonDA, GhaniA, JohnstonNJ, ConyersL, McCardleLM, . Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet2000;355:1693–4.
17.
DobsonR.First results of vCJD survey show no signs of prion. BMJ2000;320:1226.
18.
BacchettiP.Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease. Lancet2001;357:3–4.
19.
ZeidlerM, StewartG, CousensSN, EstibeiroK, WillRG.Codon 129 genotype and new variant CJD. Lancet1997;350:668.
20.
CervenakovaL, GoldfarbLG, GarrutoR, LeeHS, GajdusekDC, BrownP.Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA1998;95:13239–41.
21.
BonnD.New predictions for total vCJD mortality lower than before. Lancet2000;356:570.
22.
HiltonDA.vCJD-predicting the future? Neuro-pathol Appl Neurobiol2000;26:405–7.
23.
TurnerM.The impact of new-variant Creutzfeldt-Jakob disease on blood transfusion practice. Br J Haematol1999;106:842–50.
24.
IngrossoL, PisaniF, PocchiariM.Transmission of the 263K scrapie strain by the dental route. J Gen Virol1999;80:3043–7.
25.
Blanquet-GrossardF, SazdovitchV, JeanA, DeslysJP, DormontD, HauwJJ, . Prion protein is not detectable in dental pulp from patients with Creutzfeldt-Jakob disease. J Dent Res2000;79:700.
26.
WhitworthCL.BSE and dentistry. Br Dent J2001;190:407.
TaylorDM.Inactivation of transmissible degenerative encephalopathy agents: A review. Vet J2000;159:10–7.
29.
Department of Health.Management of possible exposure to CJD through medical procedures. A consultation paper, 2001. http://doh.gov.uk/cjd/consultation
30.
ZobeleyE, FlechsigE, CozzioA, EnariM CW.Infectivity of scrapie prions bound to a stainless steel surface. Mol Med1999;5:240–3.
31.
HarknessN, DaviesEH.The cleaning of dental diamond burs. Br Dent J1983;154:42–5.
32.
JohnsonMA, PrimackPD, LoushineRJ, CraftDW.Cleaning of endodontic files, Part I: The effect of bioburden on the sterilization of endodontic files. J Endod1997;23:32–4.
33.
LoweAH, BurkeFTJ, McHughS, BaggJ.A survey of the use of matrix bands and their decontamination in general dental practice. Br Dent J2002;192:40–2.
34.
Advisory Committee on Dangerous Pathogens Spongiform Encephalopathy Advisory Committee. Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection. London: The Stationery Office, 1997:1–54.
35.
BaggJ, SweeneyCP, RoyKM, SharpT, SmithA.Cross infection control measures and the treatment of patients at risk of Creutzfeldt Jakob disease in UK general dental practice. Br Dent J2001;191:87–90.
36.
PorterS, ScullyC, RidgwayGL, BellJ.The human transmissible spongiform encephalopathies (TSEs): implications for dental practitioners. Br Dent J2000;188:432–6.
37.
Department of Health.Creutzfeldt-Jakob Disease: Guidance for Healthcare Workers. London: The Stationery Office, 2000.
38.
Health Service Circular.Decontamination of Medical Devices. HSC 2000/032. London: Department of Health, 2000.
39.
WadsworthJD, JoinerS, HillAF, CampbellTA, DesbruslaisM, LuthertPJ, . Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet2001;358:171–80.
40.
MacGregorI.Prion protein and developments in its detection. Transfus Med2001;11:3–14.
41.
JosefsonD.Drugs for malaria and psychosis may offer hope to people with CJD. BMJ2001;323:416B.
